DK1043025T3 - Behandling af nyrecellekarcinom - Google Patents

Behandling af nyrecellekarcinom

Info

Publication number
DK1043025T3
DK1043025T3 DK00107100T DK00107100T DK1043025T3 DK 1043025 T3 DK1043025 T3 DK 1043025T3 DK 00107100 T DK00107100 T DK 00107100T DK 00107100 T DK00107100 T DK 00107100T DK 1043025 T3 DK1043025 T3 DK 1043025T3
Authority
DK
Denmark
Prior art keywords
treatment
cell carcinoma
renal cell
renal
carcinoma
Prior art date
Application number
DK00107100T
Other languages
Danish (da)
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1043025T3 publication Critical patent/DK1043025T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00107100T 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom DK1043025T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
DK1043025T3 true DK1043025T3 (da) 2005-07-04

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00107100T DK1043025T3 (da) 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Country Status (24)

Country Link
EP (2) EP1535623B1 (de)
JP (2) JP3712914B2 (de)
CN (1) CN1367702A (de)
AR (1) AR029160A1 (de)
AT (2) ATE296638T1 (de)
AU (2) AU777406B2 (de)
BR (1) BR0009644A (de)
CA (1) CA2303752A1 (de)
CO (1) CO5170412A1 (de)
CY (1) CY1108919T1 (de)
DE (2) DE60020442T2 (de)
DK (2) DK1043025T3 (de)
ES (2) ES2319777T3 (de)
HK (2) HK1032533A1 (de)
HU (1) HU230271B1 (de)
MX (1) MXPA00003401A (de)
MY (1) MY155221A (de)
NO (1) NO328983B1 (de)
NZ (1) NZ514629A (de)
PE (1) PE20010026A1 (de)
PT (2) PT1535623E (de)
TW (2) TWI310314B (de)
WO (1) WO2000061174A2 (de)
ZA (1) ZA200108169B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
WO2007126950A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CZ302005B6 (cs) * 1998-03-26 2010-09-01 Schering Corporation Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo

Also Published As

Publication number Publication date
PT1043025E (pt) 2005-09-30
DE60020442D1 (de) 2005-07-07
HUP0200781A3 (en) 2002-09-30
AU777406B2 (en) 2004-10-14
HK1032533A1 (en) 2001-07-27
NO20014851L (no) 2001-12-07
NZ514629A (en) 2004-02-27
CY1108919T1 (el) 2014-07-02
TWI310314B (en) 2009-06-01
JP3712914B2 (ja) 2005-11-02
NO20014851D0 (no) 2001-10-05
WO2000061174A2 (en) 2000-10-19
HU230271B1 (hu) 2015-11-30
MXPA00003401A (es) 2002-03-08
JP2000319196A (ja) 2000-11-21
ZA200108169B (en) 2003-01-06
ES2319777T3 (es) 2009-05-12
EP1535623B1 (de) 2008-12-31
HUP0200781A2 (en) 2002-08-28
DE60020442T2 (de) 2006-05-04
DE60041291D1 (de) 2009-02-12
EP1535623A1 (de) 2005-06-01
EP1043025B1 (de) 2005-06-01
JP2001288110A (ja) 2001-10-16
PT1535623E (pt) 2009-03-19
EP1043025A3 (de) 2000-12-20
ATE419002T1 (de) 2009-01-15
ES2239953T3 (es) 2005-10-16
AU2004242454B2 (en) 2007-02-15
TW200526243A (en) 2005-08-16
MY155221A (en) 2015-09-30
WO2000061174A3 (en) 2001-01-25
CO5170412A1 (es) 2002-06-27
NO328983B1 (no) 2010-07-05
AR029160A1 (es) 2003-06-18
PE20010026A1 (es) 2001-02-05
AU2004242454A1 (en) 2005-01-20
JP4721488B2 (ja) 2011-07-13
EP1043025A2 (de) 2000-10-11
CN1367702A (zh) 2002-09-04
HK1075417A1 (en) 2005-12-16
BR0009644A (pt) 2002-01-08
AU4204400A (en) 2000-11-14
DK1535623T3 (da) 2009-04-27
ATE296638T1 (de) 2005-06-15
CA2303752A1 (en) 2000-10-08

Similar Documents

Publication Publication Date Title
DE60003693D1 (de) Kanalstromfilter
DE60021217D1 (de) Ostomievorrichtung
ATE319461T1 (de) Simethicon enthaltendes abführmittel
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK1210085T3 (da) Farmaceutiske oplösninger af levosimendan
DE60037233D1 (de) Hämofiltrationsvorrichtung
DE60024400D1 (de) Empfangsgerät
FI991476A0 (fi) Alipäästösuodatin
HK1075417A1 (en) Renal cell carcinoma treatment
DE60007475D1 (de) Filter
NO20013596L (no) Slambehandling
DE60022086D1 (de) Wasserbehandlung
DK1088010T3 (da) Fremstilling af polyolefiner
DE59911042D1 (de) Planarfilter
DE50002979D1 (de) Kabelkanal
DK199901559A (da) Stomi/brok-bandage
DE60039142D1 (de) Energiefilter
DE29907395U1 (de) Einbaugarnitur
FI113576B (fi) Suodatin
DE29810293U1 (de) Kabelkanal
DK1227795T3 (da) Lipidkompleks af alkycycliner
DE29905529U1 (de) Kabelkanal
NO994200D0 (no) Vannfilter
NO994498D0 (no) Filter
FI990725A0 (fi) Suodatin